IFNA1 and COVID-19: Pre-clinical studies of small molecules that stimulate an early IFN response show promise in animal models of COVID-19 (107, 246); treating obese patients who have been exposed to IAV or SARS-CoV-2 may help overcome the obesity-induced IFN deficit early in infection.